Pfizer Inc PFE

$29.39 -0.06 (-0.20%)

Valuation

Market cap
167,518,704,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.80
P/E (forward)
9.87
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
48,319,500
Avg volume
33,616,914
Day's range
$28.54 – $29.43
Shares out
5,699,854,000
Stochastic %K
29%
Beta
0.31
Analysts
Hold
Price target
$30.35

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

framus_morrigan Nov 9, 8:53 AM
$PFE Monthly chart so far .... Well, let's see how that rising wedge + long term resistance play out until EOY.
0 replies
GTA_Terminal Nov 9, 5:38 AM
Unusual options activity in $PFE. Money on both sides, which usually means traders expect a move but don't agree on the direction. Read the full article for the full details: https://globaltradersacademy.com/articles/pfizer-pfe-technical-levels-options-flow-mixed-between-28-74-and-29-75?utm_source=stocktwits&utm_medium=social
0 replies
Techdamentals Nov 9, 5:09 AM
$PFE spent $3.02 billion on research and development, the money it puts into developing new drugs, in July to September 2026. That is up 18.5% from $2.55 billion a year earlier, while revenue was flat at $16.58 billion. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/PFE?ref=st
1 replies
markbrogan Nov 9, 4:54 AM
$PFE Glancy Prongay Wolke & Rotter LLP Announces Investigation of EVA Live, Inc. (GOAI) on Behalf of Investors
0 replies
1point21gigawatts Nov 8, 4:38 PM
$BCRX maybe $PFE will buy us, I’d take 1:1 shares
2 replies
taxplanr Nov 8, 3:50 PM
So do you think $MRNA cancer vaccine narrative exists just so the Department of War can keep their bioweapons assault on humanity funded by the taxpayers or is that just a conspiracy theory? $BNTX $PFE https://www.instagram.com/reel/Dfd6eEsoVou/?cplk=dTZ4dzlqbzhmdWdv
1 replies
GTA_Terminal Nov 8, 9:06 AM
$PFE Options Flow Leans to Calls: A Smart-Money Check on the Stock. It's down about 4% from a week ago. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PFE&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PFE Read the full article for the full details: https://globaltradersacademy.com/articles/pfizer-pfe-options-flow-turns-bullish-a-smart-money-check-on-the-stock?utm_source=stocktwits&utm_medium=social
0 replies
openclassaction2 Nov 8, 8:19 AM
$PFE ai drug discovery still has to survive a trial, a regulator, and a payer who asks what it costs. seems like the shortcut ends at the same three doors, and each door charges full price to pass
1 replies